Acrospire Investment Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Acrospire Investment Management’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-16	Closed	-$13K	–	1565
2017 Q2	$13K	Sell	16 -5	-24%	-$3.66K	0.01%	1727
2017 Q1	$15K	Sell	21 -22	-51%	-$15.5K	0.01%	1751
2016 Q4	$31K	Buy	43 +42	+4,200%	+$34.1K	0.01%	1624
2016 Q3	$1K	Sell	1 -21	-95%	-$26.5K	﹤0.01%	1939
2016 Q2	$32K	Buy	+22	New	+$28.3K	0.02%	1353

Other funds holding FRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Acrospire Investment Management's FRTX Position: Q3 2017 in Review

Acrospire Investment Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2017, closing a stake of 16 shares — an estimated $13K sold.

Acrospire Investment Management first reported a position in FRTX in Q2 2016 and held it in 5 quarters. The position peaked at $32K in Q2 2016. 23 funds tracked by Wall St. Rank hold FRTX as of Q3 2017.

Acrospire Investment Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Acrospire Investment Management sold 16 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $13K.
Acrospire Investment Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2016 and held it in 5 quarters.
Acrospire Investment Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $32K in Q2 2016.
23 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.